Adaptimmune Therapeutics Plc (ADAP)

followers · Follow

Sector:	HEALTH CARE
Industry:	BIOTECHNOLOGY & LIFE SCIENCES
SIC:	BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:	Adrian Rawcliffe
Employees:	490
Web site:	adaptimmune.com
60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, X0, OX14 4RX 44 1235 430000

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Please log in first to see chart

Adaptimmune Therapeutics Plc YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available